Menu Search
Equities

Argent Biopharma Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RGT:ASX

Argent Biopharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.0535
  • Today's Change-0.005 / -7.76%
  • Shares traded268.07k
  • 1 Year change-61.79%
  • Beta0.1985
Data delayed at least 20 minutes, as of Feb 18 2026 04:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Argent Biopharma Ltd had revenues fall -79.74% from 891.08k to 180.57k, though the company grew net income from a loss of 17.53m to a smaller loss of 17.84m.
Gross margin24.06%
Net profit margin-9,882.75%
Operating margin-9,512.06%
Return on assets-269.25%
Return on equity--
Return on investment--
More ▼

Cash flow in AUDView more

In 2025, Argent Biopharma Ltd increased its cash reserves by 45.75%, or 321.54k. Cash Flow from Financing totalled 9.39m or 5,201.49% of revenues. In addition the company used 9.28m for operations while cash from investing totalled 208.83k.
Cash flow per share-0.2983
Price/Cash flow per share--
Book value per share-0.1196
Tangible book value per share-0.1196
More ▼

Balance sheet in AUDView more

Argent Biopharma Ltd uses little or no debt in its capital structure.
Current ratio0.1874
Quick ratio0.1752
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.